May. 21 at 5:56 PM
After a 30% slide, the risk/reward equation on GE HealthCare
$GEHC looks different to UBS.
The firm upgraded the stock to Neutral from Sell, with a
$69 price target down from
$75, as it believes the sharp pullback since January now appropriately reflects concerns around new product execution, China exposure, and inflation pressures.
Still, UBS notes its forecasts remain below management’s mid term targets and sees limited near term catalysts for the shares.
Check what Fly KPIs trends are signaling for GE Healthcare.
Sign up with thefly.com to see the news, before it’s news.
#FlyKPIs #NewsBeforeItsNews
